Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: Adamis, Astrazeneca, Azurrx, Bio-Thera Solutions, Celltrion, Daiichi Sankyo, Glenmark, Iaso, Icosavax, Immvira, Innovent, Kazia, Kyowa Kirin, Mei, Molecular Partners, Novavax, Redhill, Takeda.

Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: 4D, AB Science, Advaccine, Biogen, Bio-Thera Solutions, Brickell, Bridge, Celltrion Healthcare, Curevac, Hightide, Innovation, Kaken, Neuren, Qbiotics, Transcenta, Valneva.

Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: Aim Immunotech, Antengene, Connect Biopharma, Cstone, Daewoong, Elixirgen, Eqrx, Glaxosmithkline, Incyte, Innovation, Innovent, Moderna, Molecular Partners, Nabriva Therapeutics Ireland, Novartis, Omeros, Ose Immunotherapeutics, Prosit Sole, RDIF, Sanofi, Sinovant Sciences, Telix, Turning Point, Zai Lab.

Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: Apeiron, Astellas, Beigene, Bergenbio, Biontech, Cynata, Daewoong, Glaxosmithkline, I-Mab, Laurent, Medicago, Meiji Seika, Pfizer, Seagen, Sosei, Takeda, Transcenta, Veru.

Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: Algernon, Antengene, Appili, Arcturus, Biophytis, Constant, Exscientia, Glaxosmithkline, Harbour Biomed, Innovation, Noxopharm, Providence, Regeneron, Reistone, Sanofi, Sumitomo Dainippon.

Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: Adagio, Arch Biopartners, Ascletis, Astrazeneca, Bionomics, Daiichi Sankyo, Diffusion, Gennova, HDT, Humanigen, Immunic, Inovio, Isofol Medical, Moderna, Novavax, Telix, Vaxart.

Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: Abbvie, Aim Immunotech, Alphamab Oncology, Ampio, Arrowhead, Atea, Beigene, Brii, Cardiol, Cstone, Eiger, Hutchison China Meditech, Innovation, Mesoblast, Novavax, Noxopharm, Organicell Regenerative Medicine, Partner, Quantum Leap Healthcare Collaborative, Reithera, Revance, Reven Holdings, Shanghai Fosun, Synairgen, Takeda.

Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: Advita Life Science, Bioarctic, Brii, Can-Fite, Chimeric, Corat, Eisai, I-Mab, Kancera, Kintor, Lipidor, Medincell, Obi, Ocugen, Oncotelic, Organicell Regenerative Medicine, Relief, SAB, Shanghai Junshi, Sorrento, Trevena, Valneva, VBI Vaccines, Verona, Vir.

Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: Adagio, Adlai Nortye, Aegis Life, Anji, Ardelyx, Atriva, Bergenbio, Covis, Gannex, H. Lundbeck, Implicit, Kinarus, Kintor, Kyowa Kirin, Mei, Merck, Nervgen, Novavax, Otsuka, Pharmabcine, Prexa Sante, Quantum Leap Healthcare, Recce, Ridgeback, Rigel, Romark Laboratories, Takeda, Todos Medical, Transcenta, Urovant Sciences.

Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: ABL, Aim Immunotech, Akston, Algernon, Antengene, Astrazeneca, Azurrx, Beigene, Bridge, Cytodyn, Daiichi Sankyo, Dynavax, Eli Lilly, I-Mab, Immunitybio, Incyte, Kiniksa, Laurent, Molecular Partners, Neurorx, Novartis, Novavax, Redhill, Regeneron, Relief, Roche, Union, Valneva.